.png?sfvrsn=b8840fbb_0 "Kalie Tommerdahl")
Kalie Tommerdahl MD
(She/Her)
Level V Resident, Graduate Medical Education, Department of Pediatrics, Section of Endocrinology, Metabolism, and Diabetes, Barbara Davis Center, University of Colorado School of Medicine
- Graduate Medical Education (SOM)
Email Address:kalie.tommerdahl@cuanschutz.edu
Background
Kalie Tommerdahl, MD, received her BA from Northwestern University in Evanston, Illinois and her MD from Northwestern University Feinberg School of Medicine in Chicago, IL. She currently sees patients in the Endocrinology and the Lifestyle Medicine Tier 2 clinics at Children’s Hospital Colorado and in the Pediatric Type 1 Diabetes Clinic at Barbara Davis Center for Diabetes.
Research + Funding
In 2019, Dr. Tommerdahl received funding from the Ludeman Center for her research project titled, “Sex-Related Differences in the Metabolic and Renal Effects of Automated Insulin Delivery Systems in Youth with Type 1 Diabetes.” Her research investigated the gap in knowledge between glycemic changes seen with Automated Insulin Delivery (AID) systems and the impact on markers of long-term cardiovascular and renal complications in both females and males with type 1 diabetes and evaluated for the presence of sex-differences which could provide invaluable, novel insight into factors that improve the morbidity and mortality risk in women with type 1 diabetes.
“I value the tremendous amount of support that the Ludeman Center provides to early career scientists in the form of research seed grants, mentorship opportunities, networking and researcher training sessions. This support has been instrumental to my success as a physician scientist.”—Dr. Tommerdahl
Transforming Women’s Health
She was inspired to help the advancement of women’s health research early on in her training when she was a pediatric endocrinologist learning about the sex differences in early kidney and cardiac disease in youth and young adults with type 1 and type 2 diabetes. Her current research priority is to help develop novel strategies to combine the positive effects of diabetes technologies and adjunctive pharmacologic therapies to improve insulin sensitivity and cardiorenal health in youth and young adults with diabetes.
